A review of nutrients and botanicals in the integrative management of cognitive dysfunction.
@article{Kidd1999ARO, title={A review of nutrients and botanicals in the integrative management of cognitive dysfunction.}, author={Parris M. Kidd}, journal={Alternative medicine review : a journal of clinical therapeutic}, year={1999}, volume={4 3}, pages={ 144-61 } }
Dementias and other severe cognitive dysfunction states pose a daunting challenge to existing medical management strategies. An integrative, early intervention approach seems warranted. Whereas, allopathic treatment options are highly limited, nutritional and botanical therapies are available which have proven degrees of efficacy and generally favorable benefit-to-risk profiles. This review covers five such therapies: phosphatidylserine (PS), acetyl-l-carnitine (ALC), vinpocetine, Ginkgo biloba…
110 Citations
Role of Traditional Medicine in Neuropsychopharmacology
- Biology
- 2009
Since allopathic system of medicine provides radical cure so more concentration is provided on natural products to cure dementia, and some excellent results with certain plants justified their use as memory enhancer.
Neuropharmacological review of the nootropic herb Bacopa monnieri.
- BiologyRejuvenation research
- 2013
This review synthesizes behavioral research with neuromolecular mechanisms putatively involved with the low-toxicity cognitive enhancing action of Bacopa monnieri (BM), a medicinal Ayurvedic herb, to integrate molecular neuroscience with behavioral research.
Dietary Flavonoids as Potential Neuroprotectants
- BiologyBiological chemistry
- 2002
Emerging findings suggest a variety of potential mechanisms of action of flavonoids and their bioavailable metabolites in cytoprotection against oxidative stress, which may be independent of conventional antioxidant reducing activities.
“Brain-Specific” Nutrients: A Memory Cure?
- Psychology, BiologyPsychological science in the public interest : a journal of the American Psychological Society
- 2002
Experimental evaluations of several widely marketed nonprescription compounds claimed to be memory enhancers and treatments for age-related memory decline suggest that future evaluations of the possible memory benefits of these supplements might fruitfully focus on memory processes rather than on memory tests per se.
Phosphatidylserine (PS) as a potential nutraceutical for canine brain aging: A review
- Biology, Psychology
- 2008
A possible emerging role of phytochemicals in improving age-related neurological dysfunctions: a multiplicity of effects.
- MedicineFree radical biology & medicine
- 2001
The Use of Ginkgo Biloba L. as a Neuroprotective Agent in the Alzheimer’s Disease
- BiologyFrontiers in Pharmacology
- 2021
By exploring more about the pathogenesis of the disease and the benefits of G. biloba extract for patients with Alzheimer’s disease, it will be possible to create an individualized therapeutic protocol to optimize the treatment.
References
SHOWING 1-10 OF 102 REFERENCES
A Placebo-Controlled, Double-blind, Randomized Trial of an Extract of Ginkgo Biloba for Dementia
- Medicine, Psychology
- 1997
EGb was safe and appears capable of stabilizing and, in a substantial number of cases, improving the cognitive performance and the social functioning of demented patients for 6 months to 1 year.
Natural substances in psychiatry (Ginkgo biloba in dementia).
- Psychology, MedicinePsychopharmacology bulletin
- 1995
In a pilot bioequivalency study, the effects of three different commercially available EGb products were examined and indicated significant quantitative central nervous system (CNS) effects in, at least, one of the three.
Tetrahydroaminoacridine in Alzheimer's dementia: Clinical and biochemical results of a double‐blind crossover trial
- Medicine, Psychology
- 1991
The results indicate that THA has a therapeutic potential, although its pharmacokinetic profile and its liability to induce liver damage may limit the clinical use of the drug in the future.
Long‐term acetyl‐L‐carnitine treatment in Alzheimer's disease
- Psychology, MedicineNeurology
- 1991
After 1 year, both the treated and placebo groups worsened, but the treated group showed a slower rate of deterioration in 13 of the 14 outcome measures, reaching statistical significance for the Blessed Dementia Scale, logical intelligence, verbal critical abilities, long-term verbal memory, and selective attention.
Effects of phosphatidylserine therapy in geriatric patients with depressive disorders
- Psychology, MedicineActa psychiatrica Scandinavica
- 1990
BC‐PS induced consistent improvement of depressive symptoms, memory and behaviour and no changes in amine metabolite levels or in hormonal responses to α2‐adrenoceptor stimulation were observed.
Clinical and neurochemical effects of acetyl-L-carnitine in Alzheimer's disease
- Medicine, BiologyNeurobiology of Aging
- 1995
Role of acetyl-L-carnitine in the treatment of cognitive deficit in chronic alcoholism.
- PsychologyInternational journal of clinical pharmacology research
- 1990
It is concluded that acetyl-L-carnitine can be a useful and safe therapeutic agent in the subtle cognitive disturbances of chronic alcoholics.
Acetyl‐L‐Carnitine in dementia
- Psychology, Medicine
- 1991
In this small trial, acetyl‐l‐carnitine was shown to be non‐toxic and possibly beneficial and further large‐scale trials are needed over long periods of time.
A 1-year multicenter placebo-controlled study of acetyl-L-carnitine in patients with Alzheimer's disease
- Medicine, PsychologyNeurology
- 1996
The study suggests that a subgroup of AD patients aged 65 or younger may benefit from treatment with ALCAR whereas older individuals might do more poorly, however, these preliminary findings are based on post hoc analyses.
Efficacy and tolerance of vinpocetine in ambulant patients suffering from mild to moderate organic psychosyndromes.
- Psychology, MedicineInternational clinical psychopharmacology
- 1991
It is demonstrated the usefulness and efficacy of vinpocetine in the management of patients with moderate organic psychosyndromes and was also superior to placebo in ratings of the "severity of illness".